Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy
- 30 July 2024
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (10) , 2483-2508
Abstract
With the continuous development of genetics in healthcare, there has been a significant contribution to the development of precision medicine, which is ultimately aimed at improving the care of patients. Generally, drug treatments used in Oncology are characterized by a narrow therapeutic range and by their potential toxicity. Knowledge of pharmacogenomics and pharmacogenetics can be very useful in the area of Oncology, as they constitute additional tools that can help to individualize patients' treatment. This work includes a description of some genes that have been revealed to be useful in the field of Oncology, as they play a role in drug prescription and in the prediction of treatment response.Keywords
This publication has 135 references indexed in Scilit:
- PD‐L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD‐L1‐low and ‐negative patients with non‐small cell lung cancerJournal of Extracellular Vesicles, 2024
- UGT1A1 genotype‐guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN‐38 concentrationInternational Journal of Cancer, 2023
- An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized MedicineClinical Pharmacology & Therapeutics, 2021
- Estrogen receptor‐low breast cancer: Biology chaos and treatment paradoxCancer Communications, 2021
- Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 UpdateClinical Pharmacology & Therapeutics, 2018
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 UpdateClinical Pharmacology & Therapeutics, 2017
- KRAS mutation in lung metastases from colorectal cancer: prognostic implicationsCancer Medicine, 2015
- Clinical delineation and natural history of the PIK3CA‐related overgrowth spectrumAmerican Journal of Medical Genetics Part A, 2014
- DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FUMedical Oncology, 2007
- BRCA1 and BRCA2 - breast cancer susceptibility genesJournal of Cancer Research and Clinical Oncology, 2000